[ad_1]
Professor of pharmacoepidemiology at London School of Hygiene and Tropical Medicine, Stephen Evans, commented on the findings.
“The overall message is that, even if the Oxford/AstraZeneca vaccine does have an increased risk of ITP, its benefit outweighs its risk.
“For the majority of people ITP does not cause serious problems but it is not the case for everyone.”
On balance, a person would be more at risk of serious illness or death by catching coronavirus.
[ad_2]
